Nurix Therapeutics CSO exercises options, sells stock
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Nurix Therapeutics, Inc. reported that Chief Scientific Officer Gwenn Hansen exercised employee stock options for 4,356 shares at an exercise price of $1.8600 per share and sold 4,356 common shares at $25.0000 per share on August 5, 2026 under a Rule 10b5-1 trading plan. After the exercise, 62,310 options from this grant remained outstanding, with an option expiration date of 2029-08-28.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) F1, F2 | 4,356 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 4,356 | $1.86 | $8K |
| Sale | Common Stock F1 | 4,356 | $25.00 | $109K |
Footnotes (2)
- F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- F2. The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
Employee Stock Option (right to buy) financial
derivative security financial
vested as to 1/48 financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Nurix Therapeutics (NRIX) disclose for Gwenn Hansen?
How many Nurix Therapeutics (NRIX) options does Gwenn Hansen retain after this transaction?
What is the vesting schedule of the exercised NRIX stock options for Gwenn Hansen?
Were Gwenn Hansen’s NRIX trades made under a Rule 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.